[CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma].

doi:10.1016/s0151-9638(06)71042-0

Article

[CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma].

Annales de dermatologie et de venereologie - 1 Oct 2006

Templier I, Charles J, Combe M-C, Bressac de Paillerets B, Leroux D, Leccia M-T

Abstract excerpt

BACKGROUND: Cutaneous melanoma is a complex disease involving genetic and environmental factors. Levodopa has been incriminated in the development and/or progression of melanoma. OBSERVATION: We report the case of a man treated with levodopa and a dopadecarboxylase inhibitor for Parkinson's disea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

[CDKN2A gene mutation and loss of p16 protein activity in a patient on levodopa presenting sporadic multiple primary melanoma].

Abstract excerpt

Topics

Related research